OOIR: Observatory of International Research

Papers

(The TQCC of SLAS Discovery is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones	160
RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery	120
Probing the SAM Binding Site of SARS-CoV-2 Nsp14 In Vitro Using SAM Competitive Inhibitors Guides Developing Selective Bisubstrate Inhibitors	50
Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations	49
A Critical and Concise Review of Mass Spectrometry Applied to Imaging in Drug Discovery	42
High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2	38
Cryo-EM: The Resolution Revolution and Drug Discovery	37
Comparison of Cell and Organoid-Level Analysis of Patient-Derived 3D Organoids to Evaluate Tumor Cell Growth Dynamics and Drug Response	37
Phenotypic Profiling of Reference Chemicals across Biologically Diverse Cell Types Using the Cell Painting Assay	36
Recommended Guidelines for Developing, Qualifying, and Implementing Complex In Vitro Models (CIVMs) for Drug Discovery	34
High-Throughput Mass Spectrometry for Hit Identification: Current Landscape and Future Perspectives	32
High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids	31
Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry	30
Discovery of Drug-Like Ligands for the Mac1 Domain of SARS-CoV-2 Nsp3	29
Identification of Compounds for Butyrylcholinesterase Inhibition	26
Selecting Approaches for Hit Identification and Increasing Options by Building the Efficient Discovery of Actionable Chemical Matter from DNA-Encoded Libraries	26
Acoustic Ejection Mass Spectrometry: A Fully Automatable Technology for High-Throughput Screening in Drug Discovery	25
Target Validation Using PROTACs: Applying the Four Pillars Framework	24
A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19	24
High-Content Phenotypic Profiling in Esophageal Adenocarcinoma Identifies Selectively Active Pharmacological Classes of Drugs for Repurposing and Chemical Starting Points for Novel Drug Discovery	23
Target-Directed Approaches for Screening Small Molecules against RNA Targets	22
CDK Family PROTAC Profiling Reveals Distinct Kinetic Responses and Cell Cycle–Dependent Degradation of CDK2	22
A High-Throughput RNA Displacement Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex toward Developing Therapeutics for COVID-19	22
High-Throughput Quantitative Assay Technologies for Accelerating the Discovery and Optimization of Targeted Protein Degradation Therapeutics	21
Changing the HTS Paradigm: AI-Driven Iterative Screening for Hit Finding	21

A Framework for Optimizing High-Content Imaging of 3D Models for Drug Discovery	20
A Tale of Two Tails: Efficient Profiling of Protein Degraders by Specific Functional and Target Engagement Readouts	20
A High-Throughput Radioactivity-Based Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex	20
Discovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection	20
Application of High-Throughput Automated Patch-Clamp Electrophysiology to Study Voltage-Gated Ion Channel Function in Primary Cortical Cultures	19
Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19	19
Using chemical and biological data to predict drug toxicity	18
Identification of potent small molecule inhibitors of SARS-CoV-2 entry	18
Public-Private Partnerships: Compound and Data Sharing in Drug Discovery and Development	17
Lead identification using 3D models of pancreatic cancer	17
Applied Biophysical Methods in Fragment-Based Drug Discovery	17
Comparative Analysis of Multiple Immunoassays for Cytokine Profiling in Drug Discovery	17
Exploring the Lower Limit of Individual DNA-Encoded Library Molecules in Selection	17
Validating ADME QSAR Models Using Marketed Drugs	17
Comparison of Approaches for Determining Bioactivity Hits from High-Dimensional Profiling Data	16
Evaluating Very Deep Convolutional Neural Networks for Nucleus Segmentation from Brightfield Cell Microscopy Images	16
In Vitro three-dimensional (3D) cell culture tools for spheroid and organoid models	16
Label-Free Screening of SARS-CoV-2 NSP14 Exonuclease Activity Using SAMDI Mass Spectrometry	16
MALDI-TOF-Based Affinity Selection Mass Spectrometry for Automated Screening of Protein–Ligand Interactions at High Throughput	16
Small-Molecule Degraders beyond PROTACs—Challenges and Opportunities	16
ASCT1 and ASCT2: Brother and Sister?	16
Z’ Does Not Need to Be > 0.5	15
Efficiency Improvements and Discovery of New Substrates for a SARS-CoV-2 Main Protease FRET Assay	15
Development of High-Throughput Assays for Evaluation of Hematopoietic Progenitor Kinase 1 Inhibitors	15
Secretome-Based Screening in Target Discovery	15
A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry	15
Arrayed CRISPR Screening Identifies Novel Targets That Enhance the Productive Delivery of mRNA by MC3-Based Lipid Nanoparticles	15
COMPARE Analysis, a Bioinformatic Approach to Accelerate Drug Repurposing against Covid-19 and Other Emerging Epidemics	14
A Scalable Approach Reveals Functional Responses of iPSC Cardiomyocyte 3D Spheroids	14
waveRAPID—A Robust Assay for High-Throughput Kinetic Screens with the Creoptix WAVEsystem	14
Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening	14
Screening Technologies for Inward Rectifier Potassium Channels: Discovery of New Blockers and Activators	14
CRISPR Meets Zebrafish: Accelerating the Discovery of New Therapeutic Targets	14
Advanced High-Content-Screening Applications of Clonogenicity in Cancer	14
The Problems of Applying Classical Pharmacology Analysis to Modern In Vitro Drug Discovery Assays: Slow Binding Kinetics and High Target Concentration	14
The Impact of Variable Selection Coverage on Detection of Ligands from a DNA-Encoded Library Screen	13
Brief Guide: Experimental Strategies for High-Quality Hit Selection from Small-Molecule Screening Campaigns	13
A Method for Determining the Kinetics of Small-Molecule-Induced Ubiquitination	13
CETSA MS Profiling for a Comparative Assessment of FDA-Approved Antivirals Repurposed for COVID-19 Therapy Identifies TRIP13 as a Remdesivir Off-Target	12
Combining Supervised and Unsupervised Machine Learning Methods for Phenotypic Functional Genomics Screening	12
HighVia—A Flexible Live-Cell High-Content Screening Pipeline to Assess Cellular Toxicity	12
The Vital Role of Proteomics in Characterizing Novel Protein Degraders	12
A Pilot Screen of a Novel Peptide Hormone Library Identified Candidate GPR83 Ligands	11
Optimization of a Colorimetric Assay to Determine Lactate Dehydrogenase B Activity Using Design of Experiments	11
Activity-Based Screening Assay for Mono-ADP-Ribosylhydrolases	11
Detection and impact of hypoxic regions in multicellular tumor spheroid cultures formed by head and neck squamous cell carcinoma cells lines	11
Ion Channels and Relevant Drug Screening Approaches	11
High-Throughput Image-Based Aggresome Quantification	11
Development of a High-Throughput Screening Assay to Identify Inhibitors of the Major M17-Leucyl Aminopeptidase from Trypanosoma cruzi Using RapidFire Mass Spectrometry	10
Fragment-based screening: A new paradigm for ligand and target discovery	10

Direct Comparison of Label-Free Biosensor Binding Kinetics Obtained on the Biacore 8K and the Carterra LSA	10
Development of a Novel Label-Free and High-Throughput Arginase-1 Assay Using Self-Assembled Monolayer Desorption Ionization Mass Spectrometry	10
Characterizations of the Urate Transporter, GLUT9, and Its Potent Inhibitors by Patch-Clamp Technique	10
Identification of a Triple Drug Combination That Is Synergistically Cytotoxic for Triple-Negative Breast Cancer Cells Using a Novel Combination Discovery Approach	10
A Perspective on Synthetic Biology in Drug Discovery and Development—Current Impact and Future Opportunities	10
Luminescence Energy Transfer–Based Screening and Target Engagement Approaches for Chemical Biology and Drug Discovery	10
deepOrganoid: A brightfield cell viability model for screening matrix-embedded organoids	10
Development of a Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay for the Inhibition of Keap1–Nrf2 Protein–Protein Interaction	10
Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication	10
Epithelial Barrier Integrity Profiling: Combined Approach Using Cellular Junctional Complex Imaging and Transepithelial Electrical Resistance	9
Operationalizing the Use of Biofabricated Tissue Models as Preclinical Screening Platforms for Drug Discovery and Development	9
Identification of Small-Molecule Inhibitors of Neutral Ceramidase (nCDase) via Target-Based High-Throughput Screening	9
Point-of-use, automated fabrication of a 3D human liver model supplemented with human adipose microvessels	9
A High-Throughput Image Cytometry Method for the Formation, Morphometric, and Viability Analysis of Drug-Treated Mammospheres	9